Gossamer Bio (GOSS) Competitors $0.71 -0.01 (-1.38%) (As of 11/19/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends GOSS vs. SVA, TRDA, CRMD, STOK, AVXL, NUVB, TRML, PHAT, IMNM, and ORICShould you be buying Gossamer Bio stock or one of its competitors? The main competitors of Gossamer Bio include Sinovac Biotech (SVA), Entrada Therapeutics (TRDA), CorMedix (CRMD), Stoke Therapeutics (STOK), Anavex Life Sciences (AVXL), Nuvation Bio (NUVB), Tourmaline Bio (TRML), Phathom Pharmaceuticals (PHAT), Immunome (IMNM), and ORIC Pharmaceuticals (ORIC). These companies are all part of the "medical" sector. Gossamer Bio vs. Sinovac Biotech Entrada Therapeutics CorMedix Stoke Therapeutics Anavex Life Sciences Nuvation Bio Tourmaline Bio Phathom Pharmaceuticals Immunome ORIC Pharmaceuticals Sinovac Biotech (NASDAQ:SVA) and Gossamer Bio (NASDAQ:GOSS) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, community ranking, institutional ownership, dividends, risk, profitability, media sentiment and valuation. Which has more volatility and risk, SVA or GOSS? Sinovac Biotech has a beta of 0.01, meaning that its stock price is 99% less volatile than the S&P 500. Comparatively, Gossamer Bio has a beta of 1.96, meaning that its stock price is 96% more volatile than the S&P 500. Does the MarketBeat Community believe in SVA or GOSS? Sinovac Biotech received 106 more outperform votes than Gossamer Bio when rated by MarketBeat users. Likewise, 67.99% of users gave Sinovac Biotech an outperform vote while only 66.23% of users gave Gossamer Bio an outperform vote. CompanyUnderperformOutperformSinovac BiotechOutperform Votes25767.99% Underperform Votes12132.01% Gossamer BioOutperform Votes15166.23% Underperform Votes7733.77% Is SVA or GOSS more profitable? Sinovac Biotech's return on equity of 0.00% beat Gossamer Bio's return on equity.Company Net Margins Return on Equity Return on Assets Sinovac BiotechN/A N/A N/A Gossamer Bio N/A -127.28%-22.12% Do analysts rate SVA or GOSS? Gossamer Bio has a consensus price target of $9.20, suggesting a potential upside of 1,187.07%. Given Gossamer Bio's stronger consensus rating and higher possible upside, analysts plainly believe Gossamer Bio is more favorable than Sinovac Biotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sinovac Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Gossamer Bio 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media prefer SVA or GOSS? In the previous week, Gossamer Bio had 8 more articles in the media than Sinovac Biotech. MarketBeat recorded 8 mentions for Gossamer Bio and 0 mentions for Sinovac Biotech. Gossamer Bio's average media sentiment score of 0.58 beat Sinovac Biotech's score of 0.00 indicating that Gossamer Bio is being referred to more favorably in the news media. Company Overall Sentiment Sinovac Biotech Neutral Gossamer Bio Positive Which has higher earnings and valuation, SVA or GOSS? Sinovac Biotech has higher revenue and earnings than Gossamer Bio. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSinovac Biotech$448.27M1.44-$99.92MN/AN/AGossamer Bio$105.32M1.54-$179.82M-$0.32-2.23 Do insiders & institutionals have more ownership in SVA or GOSS? 81.2% of Gossamer Bio shares are held by institutional investors. 12.8% of Sinovac Biotech shares are held by insiders. Comparatively, 5.0% of Gossamer Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. SummaryGossamer Bio beats Sinovac Biotech on 8 of the 15 factors compared between the two stocks. Ad Colonial MetalsTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code… And since then… "In the know" patriots have quietly used this same "Trump revenge loophole" to shield their life savings from Bidenomics…Get Your Free Gold Guide Get Gossamer Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for GOSS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GOSS vs. The Competition Export to ExcelMetricGossamer BioPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$161.98M$6.39B$5.00B$8.83BDividend YieldN/A8.11%5.18%4.07%P/E Ratio-2.239.94131.3717.48Price / Sales1.54386.021,253.1599.42Price / CashN/A22.1633.2632.45Price / Book2.555.414.654.65Net Income-$179.82M$153.11M$118.24M$225.37M7 Day Performance-12.36%-4.23%-2.45%-2.13%1 Month Performance-25.70%-8.68%-4.02%-0.20%1 Year Performance-14.71%27.80%29.46%24.41% Gossamer Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GOSSGossamer Bio4.4535 of 5 stars$0.71-1.4%$9.20+1,187.1%-13.1%$161.98M$105.32M-2.23180Short Interest ↓SVASinovac BiotechN/A$6.47flatN/AN/A$644.67M$448.27M0.003,261High Trading VolumeTRDAEntrada Therapeutics2.0931 of 5 stars$17.58-1.5%N/A+9.6%$657.84M$129.01M11.06110CRMDCorMedix2.9003 of 5 stars$10.79+4.5%N/A+176.1%$654.74M$60,000.00-13.3230Insider SellingGap DownSTOKStoke Therapeutics3.8795 of 5 stars$12.16+1.1%N/A+175.1%$644.08M$16.74M-5.79100AVXLAnavex Life Sciences3.3621 of 5 stars$7.41-0.5%N/A+31.4%$628.34MN/A-14.8240Upcoming EarningsNUVBNuvation Bio2.7579 of 5 stars$2.52-4.2%N/A+87.7%$628.09MN/A-1.1660Gap DownTRMLTourmaline Bio1.9653 of 5 stars$24.16-4.7%N/A+40.9%$619.46MN/A-8.5744PHATPhathom Pharmaceuticals2.0344 of 5 stars$8.94+1.8%N/A+24.9%$611.32M$680,000.00-1.57110IMNMImmunome1.6158 of 5 stars$9.66-2.4%N/A+17.5%$602.98M$14.02M-1.1940Analyst RevisionORICORIC Pharmaceuticals4.2461 of 5 stars$8.52+0.2%N/A+30.0%$601.26MN/A-4.7380Analyst Revision Related Companies and Tools Related Companies SVA Competitors TRDA Competitors CRMD Competitors STOK Competitors AVXL Competitors NUVB Competitors TRML Competitors PHAT Competitors IMNM Competitors ORIC Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:GOSS) was last updated on 11/20/2024 by MarketBeat.com Staff From Our PartnersTrump won. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will ...Weiss Ratings | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredAmazon's $150B Data Center Bet—What It Means for Uranium InvestorsAmazon is placing a massive bet on nuclear energy to power its $150 billion data center expansion. With dem...The Bull Report | SponsoredThe Stock Powering Musk’s AI Revolution—RevealedImagine being able to invest in Tesla, PayPal, or SpaceX before the world knew their potential. Today, you ...InvestorPlace | SponsoredTrump’s EPIC Stock Market RallyPutting HUGE gain chances in the hands of hardworking, patriotic Americans like YOU. In fact, according to ...Paradigm Press | SponsoredFormer Trump advisor releases terrifying warningGoldman Sachs: 300 Million People Are At Risk The mainstream media are practically ignoring the most import...Wide Moat Research | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gossamer Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gossamer Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GOSS Stock Alerts